Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ULTRAM ER vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits serotonin and norepinephrine reuptake.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Management of moderate to moderately severe chronic pain in adults requiring around-the-clock treatment
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
100 mg orally once daily initially, titrate up to 100 mg twice daily as needed; maximum 200 mg/day.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
The terminal elimination half-life of tramadol is approximately 6.3 hours (range 5-9 hours), while its active metabolite M1 has a half-life of about 7.4 hours. Clinically, this supports dosing every 24 hours for the extended-release formulation.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Metabolized primarily via CYP2D6 and CYP3A4; O-desmethyltramadol (M1) is the active metabolite formed by CYP2D6; tramadol and metabolites undergo further conjugation.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal excretion of tramadol and its metabolites accounts for approximately 90% of total elimination. About 10% is excreted unchanged, 30% as O-desmethyltramadol (M1), and the remainder as other minor metabolites. Biliary/fecal excretion is minimal (<10%).
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 20% bound to plasma proteins, primarily albumin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Volume of distribution is approximately 2.6-3.0 L/kg, indicating extensive tissue distribution beyond plasma volume.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral bioavailability of tramadol is approximately 75% after a single dose, increasing to 90-100% upon multiple dosing due to saturable first-pass metabolism. For ULTRAM ER, bioavailability is comparable to immediate-release formulations.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
GFR 30-80 m L/min: no adjustment; GFR <30 m L/min: avoid or extend dosing interval to 12 hours; not recommended in GFR <15 m L/min.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh Class A or B: use with caution, consider reducing total daily dose by 50%; Child-Pugh Class C: contraindicated.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Not recommended for use in pediatric patients <18 years due to risk of respiratory depression and lack of safety data.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Start at lowest dose (100 mg once daily); titrate cautiously; monitor for CNS and respiratory depression; consider reduced clearance in elderly.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion in children can be fatal; neonatal opioid withdrawal syndrome; risk of medication errors with other tramadol products; interactions with CNS depressants; serotonin syndrome; contraindicated in patients with significant respiratory depression; contraindicated in patients with acute or severe bronchial asthma; contraindicated in patients with known or suspected gastrointestinal obstruction; contraindicated in patients with previous hypersensitivity to tramadol.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Risk of respiratory depression; risk of serotonin syndrome with serotonergic drugs; risk of seizures especially in patients with epilepsy or risk factors; risk of adrenal insufficiency; risk of severe hypotension; risk of abuse and dependence; avoidance of abrupt discontinuation; use in renal or hepatic impairment; use in elderly; use in pregnancy and breastfeeding.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to tramadol or any formulation component; significant respiratory depression; acute or severe bronchial asthma in unmonitored settings; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days; use in children <12 years; use in children <18 years after tonsillectomy/adenoidectomy; use in patients with severe hepatic impairment.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid alcohol. No specific food restrictions; however, taking with food may reduce nausea. Grapefruit juice may increase tramadol levels; consider limiting grapefruit intake.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Pregnancy category C. First trimester: Limited data; avoid unless benefit outweighs risk due to potential neural tube defects. Second and third trimesters: Fetal dependence, neonatal withdrawal syndrome (seizures, irritability, respiratory depression) if used >7 days. Increased risk of preterm birth and low birth weight.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Ultram ER has an M/P ratio of 0.7-1.3. Small amounts excreted; can cause infant sedation and constipation. Use caution; monitor infant for drowsiness or feeding difficulties.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No established dose adjustments; pharmacokinetics may change in pregnancy (increased clearance, distribution volume). Use lowest effective dose; avoid sustained release if possible. Caution in third trimester due to risk of neonatal withdrawal.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
ULTRAM ER contains tramadol, an opioid agonist with SNRI properties. Do not crush or chew extended-release tablets; this can cause rapid release and fatal overdose. Use with caution in patients with seizure disorders or those taking SSRIs, SNRIs, MAOIs, or other drugs that lower seizure threshold. Avoid concurrent use with alcohol or CNS depressants. Monitor for serotonin syndrome when combined with serotonergic drugs. Do not discontinue abruptly after prolonged use; taper to avoid withdrawal symptoms. Not recommended for patients under 18. Crushing extended-release tablets is a safety hazard.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take ULTRAM ER exactly as prescribed, usually once daily. Swallow tablets whole; do not crush, chew, or break them.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) while taking this medication.,This medication has a risk of addiction, abuse, and misuse. Store securely and dispose of unused tablets properly.,Do not stop taking this medicine suddenly; withdrawal symptoms may occur. Follow your doctor's instructions for tapering.,Seek emergency medical help if you have trouble breathing, severe drowsiness, or slow heartbeat.,Inform your doctor if you have a history of seizures, head injury, or are taking antidepressants like MAOIs, SSRIs, or SNRIs.,ULTRAM ER may cause constipation, nausea, dizziness, or drowsiness. Increase fluid intake and fiber to prevent constipation.,Keep out of reach of children and pets. Accidental ingestion can be fatal.,Do not drive or operate heavy machinery until you know how ULTRAM ER affects you.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ULTRAM ER vs ABSTRAL, answered by our medical review team.
ULTRAM ER is a Opioid Analgesic that works by Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits serotonin and norepinephrine reuptake.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ULTRAM ER and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ULTRAM ER is: 100 mg orally once daily initially, titrate up to 100 mg twice daily as needed; maximum 200 mg/day.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ULTRAM ER and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ULTRAM ER is classified as Category C. Pregnancy category C. First trimester: Limited data; avoid unless benefit outweighs risk due to potential neural tube defects. Second and third trimesters: Fetal dependence, neonat. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.